Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
ABBV: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
ABBV: Leadership change
Filed 8-K for an event or period dated 2026-10-28. Leadership change.
ABBV: Financial results
Filed 8-K for an event or period dated 2026-10-30. Financial results.
ABBV: Leadership change
Filed 8-K for an event or period dated 2026-10-14. Leadership change.
ABBV: Financial results
Filed 8-K for an event or period dated 2026-10-05. Financial results.
Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CARAFATE (sucralfate) oral suspension, 1 gram (g)/10 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Public: Sep 2, 2026Original source ↗Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that NAMENDA (memantine hydrochloride) tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as the ANDAs meet relevant legal and regulatory requirements.
Public: Sep 1, 2026Original source ↗Certain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
Notice is hereby given that the U.S. International Trade Commission ("Commission") has determined not to review an initial determination ("ID") (Order No. 17) of the presiding administrative law judge ("ALJ"), terminating this investigation in its entirety based on withdrawal of the complaint.
Public: Jul 7, 2026Original source ↗Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 34 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Public: Jul 6, 2026Original source ↗Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYALEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Public: Jun 29, 2026Original source ↗Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that RECTIV (nitroglycerin) ointment, 0.4%, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Public: Jun 26, 2026Original source ↗Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
Public: Jun 8, 2026Original source ↗Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 16 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Public: Jun 3, 2026Original source ↗
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Partial coverage — some requests unavailable455 of 455 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:36 PM EST
- USAspending
- Partial coverage — some requests unavailable284 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- SAM.gov
- Not connected
- Lobbying disclosures
- Partial coverage — some requests unavailable75 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:29 PM EST
- Congress.gov
- Current across tracked companies2 of 2 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:17 PM EST
- Federal Register
- Partial coverage — some requests unavailable384 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable23 of 51 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- FEC campaign finance
- Stale — refresh overdue264 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST